Rationale: The diabetic heart is resistant to ischemic preconditioning because of diabetes-associated impairment of phosphatidylinositol 3-kinase (PI3K)-Akt signaling. The mechanism by which PI3K-Akt signaling is impaired by diabetes remains unclear. Objective: Here, we examined the hypothesis that phosphorylation of iabetes mellitus not only accelerates atherosclerosis of the coronary artery but also induces functional and structural abnormalities in the myocardium. In addition, recent studies have shown that myocardial response to ischemic preconditioning (IPC) and its mimetics is blunted or lost in diabetic hearts. 1-3 Protection afforded by IPC is triggered by activation of G protein-coupled receptors 5 and impaired activation of phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) in models of diabetes mellitus have been reported. 1-3 Our recent study 3 showed impaired activation of Jak2 and endoplasmic reticulum (ER) stress-mediated disruption of signaling from ERK to glycogen synthase kinase (GSK)-3␤ in diabetic hearts. However, the mechanism by which Jak2-mediated signaling is disabled in diabetic hearts remains unclear. In the present study, we tested the hypothesis that Jak2-mediated protection is impaired in diabetic myocardium by an angiotensin II type 1 (AT 1 ) receptor-mediated mechanism via upregulation of SOCS3 (suppressor of cytokine signaling 3)-Jak2 interaction or calcineurin.
D
iabetes mellitus not only accelerates atherosclerosis of the coronary artery but also induces functional and structural abnormalities in the myocardium. In addition, recent studies have shown that myocardial response to ischemic preconditioning (IPC) and its mimetics is blunted or lost in diabetic hearts. [1] [2] [3] Protection afforded by IPC is triggered by activation of G protein-coupled receptors 5 and impaired activation of phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) in models of diabetes mellitus have been reported. [1] [2] [3] Our recent study 3 showed impaired activation of Jak2 and endoplasmic reticulum (ER) stress-mediated disruption of signaling from ERK to glycogen synthase kinase (GSK)-3␤ in diabetic hearts. However, the mechanism by which Jak2-mediated signaling is disabled in diabetic hearts remains unclear. In the present study, we tested the hypothesis that Jak2-mediated protection is impaired in diabetic myocardium by an angiotensin II type 1 (AT 1 ) receptor-mediated mechanism via upregulation of SOCS3 (suppressor of cytokine signaling 3)-Jak2 interaction or calcineurin.
Methods
Male Otsuka-Long-Evans-Tokushima fatty (OLETF) rats, which spontaneously develop obesity and type 2 diabetes, and their controls (Long-Evans-Tokushima-Otsuka [LETO] rats) were used. Preparation of myocardial infarction, immunoblotting, quantitative real-time RT-PCR, calcineurin activity assay, and determination of insulin sensitivity were performed by standard methods (see the expanded
Protocols In Vivo
OLETF and LETO rats received saline, erythropoietin (EPO), [D-Ala2, D-Leu5]-enkephalin acetate (DADLE) (a ␦-opioid receptor agonist) or AG490 (a Jak2 inhibitor) plus DADLE 15 minutes before 20-minute coronary occlusion/2-hour reperfusion or an inhibitor of GSK-3␤, 6-bromo-indirubin-3Ј-oxime (BIO, 0.08 mg/kg, IV), 5 minutes before reperfusion. Separate groups of rats were pretreated with a AT 1 
Protocols In Vitro
Rat hearts were isolated and perfused with Krebs-Henseleit buffer in Langendorff mode, and ventricular tissues were sampled less than baseline conditions and 15 minutes after EPO infusion. In a group of hearts, FK506 was infused for 30 minutes from 15 minutes before the EPO infusion. Separate groups of rats were pretreated with valsartan for 2 weeks or FK506 for 1 week before isolation of hearts.
Statistics
Data are meansϮSEM. Differences between treatment groups were tested by 1-way or 2-way ANOVA and the Student-Newman-Keuls post hoc test for multiple comparisons. The difference was considered significant if the probability value was Ͻ0.05.
Results
Compared with LETO rats, OLETF rats had greater body weight, higher levels of blood glucose and serum insulin, and lower M value, indicating phenotype of type 2 diabetes (Online Table I ). Pretreatment with valsartan did not modify body weight in OLETF rats but reduced plasma insulin level by 32% and increased M value by 122%, suggesting an improvement in insulin sensitivity.
Blood pressure levels, heart rates, and risk area sizes were similar in the study groups except for baseline blood pressure in rats pretreated with AT 1 receptor blockers, which was 8 mm Hg lower than in untreated rats (Online Tables II and  III) . In LETO rats, EPO and DADLE reduced infarct size as a percentage of risk area (%I/R) from 48.4Ϯ1.3% in controls to 27.7Ϯ3.4% and 24.8Ϯ5.0%, respectively (Figure 1 ). This DADLE-induced protection was blocked by AG490. Infarct size in OLETF rats (60.4Ϯ1.6%) was larger than that in LETO rats, and EPO and DADLE failed to limit infarct size (53.9Ϯ5.3% and 55.0Ϯ2.2%). However, in OLETF rats pretreated with valsartan, EPO and DADLE were protective (39.4Ϯ4.9% and 38.9Ϯ3.4%), and this effect of valsartan on EPO-induced protection was mimicked by losartan (57.8Ϯ5.9% versus 31.2Ϯ7.5%, PϽ0.05). Valsartan alone did not limit infarct size in OLETF rats, and results were the same when the dose of valsartan was increased by 5-fold (10 mg/kg per day) in post hoc experiments (54.1Ϯ9.6%). In LETO rats, infarct size or protection by EPO was not modified by valsartan pretreatment (Figure 1 ). Administration of BIO to directly inhibit GSK-3␤ similarly reduced infarct size in LETO and OLETF rats (%I/Rϭ26.8Ϯ2.5% and 27.1Ϯ3.8%, PϽ0.05 versus each control).
Protein levels of GRP78 and GRP94, ER stress chaperone proteins, in the myocardium were higher by 102% and by 114%, respectively, in OLETF than in LETO rats, and valsartan attenuated the elevation of these ER stress markers (Online Figure I) . EPO infusion increased levels of phosphoJak2 and phospho-Akt in LETO rats (Figure 2 ). EPO failed to induce Jak2 and Akt phosphorylation in OLETF rats, but responses of these kinases were preserved in OLETF rats pretreated with valsartan. There was no significant difference in the baseline level of Jak2 phosphorylation (Online Figure  II) and EPO-induced ERK1/2 phosphorylation between LETO and OLETF rats (data not shown).
There was no significant difference between total SOCS3 levels or SOCS3 levels in the Jak2 immunoprecipitates in OLETF and LETO rats (Online Figure III) 3A), although protein and mRNA levels of calcineurin were similar in the two groups (Online Figures IV and V) . Pretreatment with valsartan for 2 weeks suppressed tissue calcineurin activity similar to pretreatment with FK506 or cyclosporine A ( Figure 3A) , and chronic treatment with valsartan or FK506 restored response of Jak2 to EPO ( Figures  2A and 3B ). In contrast, Jak2 response was not recovered by acute infusion of FK506 for 30 minutes from 15 minutes before EPO infusion in isolated OLETF hearts. PTP1B and SHIP1 mRNA levels in the myocardium were similar in OLETF and LETO rats, although transforming growth factor-␤1 mRNA level was elevated in OLETF rats, as reported previously (Online Figure V) . 4 
Discussion
Earlier studies have demonstrated impairment of PI3K-Akt and ERK signaling in the myocardium of rat models of type 1 and type 2 diabetes mellitus. [1] [2] [3] However, little is known about dysfunction of signaling mechanisms upstream of PI3K and ERK. Thus, we focused on alterations by diabetes in the Jak2-mediated signaling pathway, which is crucial for both cytokine receptors and G protein-coupled receptors to transmit cytoprotective signaling. [5] [6] [7] [8] EPO and DADLE failed to activate Jak2 in OLETF rats, whereas direct inhibition of GSK-3␤ by BIO limited infarct size in OLETF and LETO rats, indicating disrupted signaling upstream of Jak2 and preserved protective mechanisms downstream of GSK-3␤ in diabetic myocardium. AT 1 receptor blockers restored both Jak2-PI3K-Akt signaling and myocardial response to EPO and DADLE in OLETF rats, although neither infarct size nor EPO-induced protection was modified by AT 1 blockade in LETO rats. These results indicate that AT 1 receptor activation is responsible for impaired Jak2 activation and interruption of cytoprotective signaling from the EPO and ␦-opioid receptors in diabetic hearts. We first assumed that SOCS3, a negative regulator of Jak2, is responsible for AT 1 receptor-mediated inhibition of Jak2 phosphorylation in the diabetic myocardium because SOCS3 has been shown to be upregulated by AT 1 receptor activation in noncardiac cells. 9 However, this possibility was not supported by the results that level of SOCS3 bound to Jak2 was similar in OLETF and LETO rats. A significant difference was not detected also for expression of SHP-1 and PTP1B, protein phosphatases involving in Jak2 dephosphorylation. 10 The hypothesis that calcineurin is responsible for lack of EPO-induced phosphorylation of Jak2 in OLETF rats was based on a report of upregulated calcineurin in the diabetic kidney 11 and a reported function of calcineurin as a Tyr protein phosphatase. 12 This hypothesis was supported by the findings that calcineurin activity was elevated by more than 2-fold in the myocardium of OLETF rats and that inhibition of calcineurin restored the response of Jak2 to EPO receptor activation ( Figure 3 ). Furthermore, blockade of the AT 1 receptor normalized calcineurin activity, indicating that AT 1 receptor mediates upregulation of calcineurin in OLETF rats. However, direct dephosphorylation of Jak2 by calcineurin is unlikely to be a mechanism by which calcineurin inhibited increase in phospho-Jak2 level after EPO receptor activation, because acute FK506 infusion could not restore response of Jak2 in OLETF rats ( Figure 3B ).
How calcineurin activity is upregulated by the AT 1 receptor in the diabetic myocardium remains unclear. In contrast to reports on calcineurin in the renal cortex of diabetic rats, 11 protein and mRNA levels of calcineurin were not elevated in OLETF myocardium (Online Figures IV and V) . Because tissue calcineurin activity was assayed less than condition of sufficiently high levels of Ca 2ϩ and calmodulin, the difference between levels of calcineurin activity in the diabetic myocardium and nondiabetic myocardium would be attributable to difference in modulatory factors other than Ca 2ϩ and calmodulin. Candidates for such factors include RCAN1 (regulator of calcineurin 1) 13 and heat shock protein-90. 14 Relationships among ER stress, Jak2 signaling, and antiinfarct tolerance of the myocardium in the diabetic heart are complex. Our previous studies have shown that PI3K-Akt and ERK pathways downstream of the EPO receptor have complementary roles in cardioprotection. 6, 7 However, in diabetic hearts, both PI3K-Akt-GSK-3␤ signaling and ERK-GSK-3␤ signaling are impaired. 2, 3 We recently found that suppression of ER stress restored ERK-GSK-3␤ signaling without recovery of Jak2-PI3K-Akt signaling. 3 Suppression of ER stress by a chemical chaperone reduced infarct size in OLETF rats to the level of infarct size in LETO rats without change in heart weight, 3 indicating that modest ventricular hypertrophy in OLETF rats is not a major cause of the infarct size difference. In the present study, blockade of the AT 1 receptor prevented both elevation of ER stress markers and loss of Jak2 phosphorylation response in diabetic hearts. Taken together, these observations indicate that blockade of the AT 1 receptor can be more proximal therapy compared with an ER stress modulator for preservation of myocardial response to Jak2-mediated cardioprotective interventions (Online Figure VI) .
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Supplement Material Expanded Methods
The present study was conducted in strict accordance with The Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and was approved by the Animal Use Committee of Sapporo Medical University.
Infarct Size Experiments In Vivo Surgical preparation OLETF and LETO rats (25-30 weeks old) were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and intubated and ventilated with a Harvard respirator (model 683, South Natick, MA) using room air and oxygen supplement. After a left thoracotomy, a coronary snare was placed around a marginal branch of the left coronary artery by using a 5-0 silk thread. Saline-filled catheters were placed in the jugular vein and the carotid artery for drug infusion and blood pressure monitoring. An electrocardiogram was recorded by bipolar electrodes on the chest. Rectal temperature was continuously monitored, and a heating lamp was used to maintain the temperature within the range of 37.5 to 38.5°C.
Pretreatment with an AT 1 receptor blocker
In rats assigned to pretreatment with an AT 1 receptor blocker, valsartan (2 mg/kg/day) or losartan (3 mg/kg/day) was administered for 14 days using an osmotic minipump (Alzet model 2002, DURECT Co.). In a post hoc series of experiments (n =3), the dose of valsartan was increased to 10 mg/kg/day.
Ischemia/reperfusion protocol
After a 20-min stabilization period, blood samples were collected from the jugular vein and rats then received no pretreatment (controls), erythropoietin (EPO, 5000 units/kg iv), [D-Ala 2 ,D-Leu 5 ]-enkephalin acetate (DADLE, 1 mg/kg iv), or AG490 (3 mg/kg iv) plus DADLE before 20-min coronary occlusion/2-hr reperfusion. EPO and DADLE were administered at 15 min before ischemia. AG 490 was injected 20 min before ischemia. At the end of 2-hr reperfusion, blockade of AT1 receptors by valsartan or losartan was confirmed by significant attenuation of blood pressure responses to serial doses of angiotensin II (0.05 μg/kg, 0.1 μg/kg and 0.5 μg/kg iv). Rats were then sacrificed by pentobarbital overdose, and hearts were excised and mounted onto a Langendorff apparatus for perfusion with saline. The coronary artery was re-occluded, and a saline suspension of fluorescent polymer microspheres (Duke Scientific Co., Palo Alto, CA) was infused into the aorta to negatively mark the area at risk. The hearts were sliced after freezing at -20°C into 2-mm-thick sections from apex to base, and stained with triphenyltetrazolium chloride (TTC) to visualize infarcts. Images of the risk areas and infarcted areas were photographed under black light and room light, respectively, and the sizes of the infarct and the area at risk were measured by SigmaScan (SPSS, Chicago, IL).
To confirm that 2-hr reperfusion is sufficient for accurate determination of infarct size by TTC staining, we determined infarct size after 20-min ischemia/24-hr reperfusion by both TTC and hematoxylin-eosin staining in three LETO rats. Infarct size by TTC staining and that by HE staining were essentially the same: 51.5±13.1% of risk area vs. 50.0±13.0% of risk area.
Furthermore, these infarct sizes were very similar to infarct size determined at 2 hr after reperfusion in LETO control (48.4±1.3) shown in Figure 1 and supplementary Table III . Schaper et al. [1] previously reported that there was no significant difference between infarct sizes which were reperfused for 48 hrs and those reperfused for only 90 min before tetrazolium staining in canine hearts. Taken together, these findings indicate that ischemia/reperfusion protocol was appropriate for infarct size determination by TTC staining in the present study.
Isolated Heart Experiments Surgical preparation and protocol Rats were not treated or were pretreated with valsartan (2 mg/kg/day) for 14 days or with FK506 (1 mg/kg/day, i.p.) or cyclosporine A (20 mg/kg/day, i.p.) for 7 days before the experiments using an osmotic minimpup. After anesthesia and ventilation as in the infarct size experiments, hearts of the rats were quickly excised and perfused with non-circulating Krebs-Henseleit buffer (NaCl 118.5, KCl 4.7, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 24.8, CaCl 2 2.5 and glucose 10 mmol/L) at a pressure of 75 mmHg as previously reported [2, 3] . The buffer was continuously gassed with 95% O 2 / 5% CO 2 , and the temperature of the perfusate was maintained at 38°C. A fluid-filled latex balloon with a PE-50 polyethylene tube was inserted into the left ventricle and was connected to an SCK-590 transducer. Coronary flow was measured by timed collection of perfusate dripping from the heart. After a 20-min stabilization period, hearts were assigned to no pretreatment, EPO infusion (10 units/ml) for 15 min or EPO and FK506 infusion (150 nM) starting 15 min before the EPO infusion. Myocardial tissues (0.2~0.3 g) were sampled from the left ventricle using sharp scissors at baseline and at 15 min after EPO infusion.
The sampled tissues were immediately frozen in liquid nitrogen and stored at -80˚C until use for biochemical analysis.
Immunoblotting
Tissue samples were homogenized in ice-cold buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail tablet (Complete, Roche Applied Science, Penzberg, Germany). The homogenate was centrifuged at 13,000 g for 15 min at 4°C to obtain the supernatant. Protein concentration was determined using a Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA). Equal amounts of protein were analyzed by immunoblot assays using antibodies that recognize the following proteins: glucose-regulated protein (GRP) 78, calcineurin A, phosphorylated Jak2 (Tyr1007/1008) and total Jak2, phosphorylated Akt (Ser473) and total Akt, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 (Cell Signaling Technology, Beverly, MA), and SOCS3 (Santa Cruz Biotechnology, Santa Cruz, CA), GRP94 (Zymed, Carlsbad, CA), and β-actin (Sigma). In a series of experiments to test the effects of EPO on kinase phosphorylation, pairs of a baseline sample and a post-EPO infusion sample from all study groups were loaded in one gel to minimize the possibility that inter-group differences are masked by a blot-to-blot difference in densitometric values. PVDF membranes were first used for blotting for phosphorylated kinases and then used for re-blotting for total kinases and for loading controls after stripping using Re-Blot Western Recycling Kit (CHEMICON International, Temecula, CA). Immunoblotted proteins were visualized by using an Immobilon Western detection kit (Millipore, Billerica, MA) and quantified by a lumino-image analyzer, LAS-2000mini (Fujifilm, Tokyo, Japan).
Immunoprecipitation
To examine interaction of Jak2 with SOCS3, Jak2 was immunoprecipitated using methods described previously [2, 3] . In brief, total tissue homogenates (2 mg) were solubilized in 1 ml of IP buffer (20 mM Tris-HCl, pH 7.4, 1 mM EGTA, 5 mM NaN 3 , 50 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 50 mM Na 3 VO 4 , 1% Triton X-100, 0.5% NP-40 and a protease inhibitor cocktail) and pre-incubated with 50 μl protein G magnetic beads (New England BioLabs, Ipswich, MA, USA) for 1 hr to remove proteins that can bind non-specifically to the beads. The supernatant was collected and incubated with anti-Jak2 antibodies (Cell Signaling Technology, Beverly, MA) for 1 hr, and the mixture was then incubated with 50 μl of fresh beads for 1 hr. A magnetic field was applied to this IP mixture, and supernatant was removed from the microcentrifuge tube. The beads were washed 2 times using 500 μl IP buffer, re-suspended in 30 μl of sodium dodecyl-sulphate (SDS) sample loading buffer (125 mM Tris-Hcl, pH 6.8, 4.3% SDS, 30% glycerol, 10% β-mercaptoethanol, 0.01% bromophenol blue) and incubated at 70°C for 5 min. Finally, 20 μl supernatant was collected after applying a magnetic field to the mixture and was used for immunoblotting with anti-SOCS3 antibodies.
Assay of calcineurin activity
Calcineurin activity was determined by using a Biomol Green TM Quantizyme TM Assay System (Calcineurin Cellular Assay Kit Plus AK-816, Biomol International, LP) according to the manufacturer's instruction. In brief, frozen tissues were homogenized in ice-cold lysis buffer (50 mM Tris, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.2% NP-40) containing a protease inhibitor. The samples were centrifuged at 100,000g for 45 min at 4°C and the supernatant was collected. The free phosphate in the supernatant was removed by passing the supernatant through a desalting column (P6 DG desalting resin) equilibrated with lysis buffer. The collected extracts (5 μg in each sample) were used for determination of calcineurin activity using calcineurin-specific RII phosphopeptide.
Quantitative real time RT-PCR Ventricular tissues were homogenized using an ultrasonic processor and mRNA was extracted by using an RNeasy Midi Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. Quantitative real-time RT-PCR analysis was performed for determination of mRNA levels of calcineurin, PTP1B, SHIP1 and TGF-β1 with an Applied Biosystems Prism 7500 Sequence Detection System (Applied Biosystems Inc., Foster City, CA) using TaqMan® universal PCR master mix according to the manufacturer's specifications. The TaqMan gene expression assays used were: Rn00667869_m1 (Ppp3cb), Rn00561821_m1 (Ptpn1), Rn00588164_m1 (Ptpn6), Rn01475964_m1 (Tgfb1) and Rn01273233_g1 (Actb). The thermal cycler conditions were as follows: hold for 10 min at 95 °C and then by two-step PCR for 40 cycles of 95 °C for 15 s followed by 60 °C for 1 min. All assays were performed in duplicate. Differences between mRNA levels in study groups were examined by the comparative Ct method [4] using endogenous β-actin (Actb) as an internal control. RT-PCR data were analyzed with Applied Biosystems Prism Sequence Detection Software following User Bulletin #2 (Applied Biosystems).
Euglycemic Hyperinsulinemic Glucose Clamp
Insulin sensitivity was determined by the euglycemic glucose clamp method as previously reported [5] . In brief, the jugular vein and the carotid artery were cannulated under anesthesia with a PE50 polyethylene tube for blood glucose monitoring and administration of the infusate. After overnight fasting (approximately 12 hr), each rat was placed in a foam plastic jacket that allowed movement of all four limbs and forward vision. At the start of the glucose clamp, fasting blood glucose level was determined, and a loading dose of insulin (25 mU/kg of Humalin R, U-40) was administered as a bolus, followed by infusion of insulin at a rate of 4 mU/kg/min for 147 min. During the glucose clamp, 12.5% glucose solution was infused as needed to maintain blood glucose at approximately 100 mg/dl. Ten μl of arterial blood was taken at 7-min intervals for determination of blood glucose to adjust glucose infusion rate. The average of the rate of glucose infusion for the last 35 min was taken as the index of insulin sensitivity (M value: mg/kg/min).
Chemicals
DADLE, angiotensin II and losartan was purchased from Sigma, Wako and LKT Laboratories, respectively, and cyclosporin A and AG 490 were obtained from Calbiochem. Recombinant human EPO, valsartan and FK506 were kindly provided by Chugai Pharmaceutical Co., Novartis Pharma AG and Astellas Pharma Inc., respectively. Humalin R insulin was purchased from Shionogi Pharmaceutical Co. In the normal myocardium, both the Jak2-PI3K-Akt signaling pathway and the Ras-ERK signaling pathway contribute to phosphorylation of GSK-3β after activation of the EPO receptor [Ref. 3, 6, 7] . Phospho-GSK-3β suppresses opening of mitochondrial permeability transition pores (mPTPs), leading to protection of cardiomyocytes from necrosis. In OLETF myocardium, the signal from Jak2 to PI3K is disrupted by failure of Jak2 phosphorylation, and the signal from ERK to GSK-3β is also compromised by failure of phospho-ERK to phosphorylate GSK-3β [Ref.3] . The present study indicates that AT 1 receptor-mediated up-regulation of calcineurin activity is responsible for lack of increase in phospho-Jak2 level after EPO receptor activation, which might be attributable to modification of a certain protein Body weight data are those from all rats in the present study. Blood samples for glucose, insulin and lipid determination were obtained from randomly selected 18 ~ 27 rats in each group used from infarct size and immunoblotting experiments . Determination of M values was performed in separate groups of rats (n = 3 in LETO, n = 7 OLETF, n = 9 OLETF+Val).
Online 
